Eshelman Ventures, LLC — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
Sapience Therapeuticssapiencetherapeutics.cominMay 2022 · $41M
Sapience Therapeutics is a clinical-stage biotechnology company developing peptide-based cancer therapies that target traditionally undruggable oncogenic proteins and protein-protein interactions.
BiotechHealthtechScarsdale, US
Barry Kappel, Ph.D.(Executive Officer, Director)Abi Vainstein-Haras(Chief Medical Officer)inMarisa Frackman(Chief Financial Officer)inSeth I. Rubin(General Counsel)in
BoardIsaac Blech(Director)Robert Ruffolo, Ph.D.(Director)
PartnerFred Eshelman· solo GP
Co-investorsConnectivity Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.